Literature DB >> 18687310

Specific increase of human kallikrein 4 mRNA and protein levels in breast cancer stromal cells.

Alain Mangé1, Caroline Desmetz, Marie-Laurence Berthes, Thierry Maudelonde, Jérôme Solassol.   

Abstract

The kallikrein family (KLK) has been implicated in cancer and may be useful as tumor markers. Here, we compared the 15 KLK genes' expression in malignant and normal breast tissues using real-time quantitative PCR. Most KLKs were expressed at lower levels in breast cancer compared to normal breast tissue. The only exception was the eightfold increase level of KLK4 in breast cancer tissues (P=0.008). KLK4 level was strongly associated with tumor grade (P=0.0015). Interestingly, based on laser cell microdissection analysis and immunochemistry, the up-regulation of kallikrein 4 occurred in the surrounding stromal cells. Our findings suggest that KLK4 may be associated with the development and progression of breast cancer and suggest its potential use in breast cancer monitoring.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18687310     DOI: 10.1016/j.bbrc.2008.07.138

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Structural characterization and expression of five novel canine kallikrein-related peptidases in mammary cancer.

Authors:  Katerina Angelopoulou; George S Karagiannis
Journal:  Mamm Genome       Date:  2010-09-19       Impact factor: 2.957

2.  Elevated levels of both microRNA 378 (miR-378) and kallikrein-related peptidase 4 (KLK4) mRNA are associated with an unfavorable prognosis in triple-negative breast cancer.

Authors:  Weiwei Gong; Caixia Zhu; Yueyang Liu; Alexander Muckenhuber; Holger Bronger; Andreas Scorilas; Marion Kiechle; Julia Dorn; Viktor Magdolen; Tobias Dreyer
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  Aberrant KLK4 gene promoter hypomethylation in pediatric hepatoblastomas.

Authors:  Baihui Liu; Ximao Cui; Shan Zheng; Kuiran Dong; Rui Dong
Journal:  Oncol Lett       Date:  2017-01-02       Impact factor: 2.967

4.  Three dysregulated miRNAs control kallikrein 10 expression and cell proliferation in ovarian cancer.

Authors:  N M A White; T-F F Chow; S Mejia-Guerrero; M Diamandis; Y Rofael; H Faragalla; M Mankaruous; M Gabril; A Girgis; G M Yousef
Journal:  Br J Cancer       Date:  2010-03-30       Impact factor: 7.640

5.  Hypomaturation enamel defects in Klk4 knockout/LacZ knockin mice.

Authors:  James P Simmer; Yuanyuan Hu; Rangsiyakorn Lertlam; Yasuo Yamakoshi; Jan C-C Hu
Journal:  J Biol Chem       Date:  2009-05-06       Impact factor: 5.157

6.  Kallikrein 11 Down-regulation in Breast Carcinoma: Correlation With Prognostic Parameters.

Authors:  Tulin Ozturk; Ecem Zeynep Kain; Mete Bora Tuzuner; Ayca Diren; Sebnem Batur; Hulya Yilmaz-Aydogan; Oguz Ozturk; Turgay Isbir
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

7.  Prognostic value of kallikrein-related peptidase 12 (KLK12) mRNA expression in triple-negative breast cancer patients.

Authors:  Weiwei Gong; Yueyang Liu; Sarah Preis; Xiaocong Geng; Agnes Petit-Courty; Marion Kiechle; Alexander Muckenhuber; Tobias Dreyer; Julia Dorn; Yves Courty; Viktor Magdolen
Journal:  Mol Med       Date:  2020-02-07       Impact factor: 6.354

Review 8.  Role of Serine Proteases at the Tumor-Stroma Interface.

Authors:  Ravichandra Tagirasa; Euna Yoo
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 9.  Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.

Authors:  Manfred Schmitt; Viktor Magdolen; Feng Yang; Marion Kiechle; Jane Bayani; George M Yousef; Andreas Scorilas; Eleftherios P Diamandis; Julia Dorn
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

10.  Expression of kallikrein-related peptidase 7 is decreased in prostate cancer.

Authors:  Chong-Yu Zhang; Yu Zhu; Wen-Bin Rui; Jun Dai; Zhou-Jun Shen
Journal:  Asian J Androl       Date:  2015 Jan-Feb       Impact factor: 3.285

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.